TB Alliance

Phase 1 clinical trial of TB drug candidate TBA-354 discontinued

More investment is needed to expand the portfolio of new TB drug candidates.

Read More →

Phase 1 TBA-354 placed on clinical hold

January 4, 2016 - TB Alliance announced today that it has voluntarily halted further dosing of TBA-354 in the ongoing Multiple Ascending Dose (MAD) Phase 1 study. This action has prompted the United States Food and Drug Administration (FDA) to place the organization’s Investigational New Drug (IND) submission for TBA-354 on clinical hold. TBA-354, which had entered Phase 1 testing in early 2015, is from the nitroimidazole class of chemicals.

Read More →

Sign a petition: Tell world leaders to end childhood tuberculosis

The petition will be open for signatures until World TB Day, March 2016, when it will be presented to world leaders.

Read More →

TB Alliance and partners announce world’s first availability of appropriate, child-friendly TB medicines in correct doses

Medication simplifies and improves treatment for 1 million children with TB; Medicines come in dispersible fixed-dose combinations at the correct dosages, tablets no longer need to be cut or crushed; These products can improve adherence and child survival from TB.

Read More →

TB Alliance launches “Nix-TB” clinical trial to test new XDR-TB treatment

First clinical trial to test a new all-oral regimen for extensively drug-resistant TB; Nix-TB is a critical step in the development of a universal treatment for all types of TB.

Read More →

Host for new TB clinical trial data-sharing platform selected

TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the TB Alliance and St. George’s, University of London.

Read More →

Australia grants support for TB Alliance to advance new TB drugs

TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB), has received a grant from the Australian Department of Foreign Affairs and Trade (DFAT) to support late-stage clinical trials of new TB treatments. The grant was announced at a World TB Day event in Canberra, Australia as part of a larger investment of support for new tools to tackle diseases that endanger public health in the region.

Read More →

TB Alliance announces partnership with U.S. Fund for UNICEF to increase access to impending new child-friendly TB treatments

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality.

Read More →

Global Phase 3 “STAND” trial launched to test new tuberculosis drug regimen PaMZ to shorten, improve treatment

STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America; Results published in The Lancet show PaMZ’s promise to dramatically shorten and simplify therapy for patients with drug-resistant TB; Regimen could improve treatment for those with drug-sensitive TB and those with HIV co-infection.

Read More →

The Lancet: Results of Phase 2b trial of novel TB regimen PaMZ show potential to shorten, improve TB treatment

Phase 3 STAND trial launched to advance PaMZ through final stage of testing.

Read More →

Page 2 of 5 · Total posts: 10

←First 1 2 3 Last→